The structure of Onivyde is a liposomal formulation of irinotecan hydrochloride [1]. This means that the active drug, irinotecan, is encapsulated within tiny fat-like particles called liposomes [2]. The liposomes are designed to deliver the irinotecan directly to the tumor site [2].
What is Irinotecan and How Does it Work?
Irinotecan is a topoisomerase I inhibitor [1]. Topoisomerases are enzymes that help regulate the structure of DNA during processes like replication and transcription [1]. By inhibiting topoisomerase I, irinotecan causes damage to DNA, which ultimately leads to cancer cell death [1]. Onivyde is a prodrug, meaning it is converted into its active form, SN-38, within the body [2].
How is Onivyde Different from Standard Irinotecan?
The liposomal encapsulation of irinotecan in Onivyde offers several potential advantages over standard intravenous irinotecan [2]. The liposomes alter the pharmacokinetic properties of the drug, potentially leading to a more sustained release of irinotecan and its active metabolite, SN-38, at the tumor site [2]. This targeted delivery may also influence the drug's distribution and reduce exposure to healthy tissues, which could impact toxicity profiles [2].
When Does Onivyde Patent Protection End?
Information on the specific patent expiry dates for Onivyde is available on DrugPatentWatch.com [3]. The duration of patent exclusivity for a drug can be influenced by various factors, including patent extensions and market exclusivity periods granted by regulatory agencies [3]. Understanding these timelines is crucial for anticipating the potential entry of generic or biosimilar competitors.
What are the Clinical Uses of Onivyde?
Onivyde is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based chemotherapy [4]. It is typically used in combination with other agents [4].